La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Shanghai MicroPort Endovascular MedTech Croissance future
Future contrôle des critères 5/6
Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 24% and 25% per annum respectively. EPS is expected to grow by 21.1% per annum. Return on equity is forecast to be 18.1% in 3 years.
Informations clés
24.0%
Taux de croissance des bénéfices
21.1%
Taux de croissance du BPA
Medical Equipment croissance des bénéfices | 22.5% |
Taux de croissance des recettes | 25.0% |
Rendement futur des capitaux propres | 18.1% |
Couverture par les analystes | Good |
Dernière mise à jour | 03 Jul 2024 |
Mises à jour récentes de la croissance future
Recent updates
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends
Aug 15Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel
Jun 29These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely
Apr 29Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem
Apr 09Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't
Mar 25Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 2,540 | 1,071 | 540 | 977 | 7 |
12/31/2025 | 1,946 | 802 | 439 | 769 | 10 |
12/31/2024 | 1,536 | 635 | 431 | 611 | 10 |
3/31/2024 | 1,260 | 552 | 458 | 651 | N/A |
12/31/2023 | 1,187 | 492 | 368 | 558 | N/A |
9/30/2023 | 1,121 | 444 | 166 | 398 | N/A |
6/30/2023 | 1,059 | 421 | 22 | 369 | N/A |
3/31/2023 | 924 | 358 | -10 | 308 | N/A |
12/31/2022 | 897 | 357 | 40 | 334 | N/A |
9/30/2022 | 839 | 367 | 133 | 340 | N/A |
6/30/2022 | 781 | 346 | 276 | 362 | N/A |
3/31/2022 | 745 | 338 | 242 | 337 | N/A |
12/31/2021 | 685 | 316 | 211 | 300 | N/A |
9/30/2021 | 652 | 302 | 248 | 299 | N/A |
6/30/2021 | 618 | 279 | 255 | 291 | N/A |
3/31/2021 | 569 | 257 | 239 | 269 | N/A |
12/31/2020 | 470 | 215 | 191 | 217 | N/A |
9/30/2020 | 414 | 192 | 148 | 174 | N/A |
6/30/2020 | 377 | 177 | 142 | 166 | N/A |
3/31/2020 | 341 | 156 | 133 | 154 | N/A |
12/31/2019 | 334 | 142 | 122 | 143 | N/A |
9/30/2019 | 306 | 127 | 117 | 138 | N/A |
6/30/2019 | 282 | 115 | 84 | 117 | N/A |
3/31/2019 | 257 | 103 | 90 | 118 | N/A |
12/31/2018 | 231 | 91 | 82 | 107 | N/A |
12/31/2017 | 165 | 63 | N/A | 69 | N/A |
12/31/2016 | 125 | 41 | N/A | 30 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 688016's forecast earnings growth (24% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 688016's earnings (24% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 688016's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 688016's revenue (25% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 688016's revenue (25% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 688016's Return on Equity is forecast to be low in 3 years time (18.1%).